Buscar
Mostrando ítems 1-3 de 3
Artículo
Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis
(Frontiers Media SA, 2021)
Background: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to ...
Artículo
Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort
(Elsevier Science BV, 2022)
Background: Few investigations have been carried out on metabolic syndrome in antipsychotic- naïve patients with schizophrenia. Methods: Our primary objective was to compare the prevalence of Metabolic Syndrome (MetS), ...
Artículo
Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis
(Oxford University Press, 2022-05-31)
Objective Aripiprazole and risperidone are 2 of the most used second-generation antipsychotics (SGAs) worldwide. Previous evidence shows a similar effect of these SGAs on weight and metabolic changes in the short term. ...